November/December 2019

COVER

2020 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

FEATURES

2020 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

CDMO SELECTION - Ready to Launch: Developing Your Biologic With an Eye Toward Commercial Supply

Stacey Treichler, PhD, believes the development process for new biologics is complex and requires a substantial amount of time and resources, and reviews some of the areas where careful choice of CDMO is key, including cell line development and cGMP manufacturing capabilities, and how an integrated approach can be beneficial.

PREFILLED SYRINGES - Selecting the Right Primary Container for Injectables in Acute Care

Alfred Harvey, MBA, MS, discusses how differences in primary container options for injectable drugs can add value by offering hospitals and care centers configurations that address universal pain points.

CONTINUOUS MANUFACTURING - Continuous Manufacturing in Pharmaceuticals: Implications for the Generics Market

Kamna Jhamb, PhD, says the highly regulated nature of the pharmaceutical sector, and the low-risk-taking nature of this market, are the two main factors that have restrained the implementation of novel methods of manufacturing by pharmaceutical industries. However, the burgeoning demand for complex and innovative therapies and rising competition have led pharmaceutical manufacturers to reconsider their methods of manufacturing.

DRUG DEVELOPMENT EXECUTIVE - ProQR: Developing RNA Therapies for Rare Genetic Disorders

Daniel de Boer, Chief Executive Officer of ProQR, discusses the use of RNA technology to directly target the underlying cause of genetic diseases.